Phase 1 Study of the Combination of Escalated Total Marrow Irradiation Using Helical Tomotherapy and Fixed High-Dose Melphalan (140 mg/m²) Followed by Autologous Stem Cell Transplantation at First Relapse in Multiple Myeloma-Reference-Cited by-同舟云学术

Phase 1 Study of the Combination of Escalated Total Marrow Irradiation Using Helical Tomotherapy and Fixed High-Dose Melphalan (140 mg/m²) Followed by Autologous Stem Cell Transplantation at First Relapse in Multiple Myeloma

Published:2023-03 Issue:3 Volume:115 Page:677-685
ISSN:0360-3016
Container-title:International Journal of Radiation Oncology*Biology*Physics
language:en
Short-container-title:International Journal of Radiation Oncology*Biology*Physics

Author:

Cailleteau Axel^ORCID,Maingon Philippe,Choquet Sylvain,Bourdais Rémi,Antoni Delphine,Lioure Bruno,Hulin Cyrille,Batard Stéphanie,Llagostera Camille,Guimas Valentine,Touzeau Cyrille,Moreau Philippe,Mahé Marc-André,Supiot Stéphane

Funder

French National Cancer Institute

French Government Ministry of Social Affairs Health and Womens Rights

Publisher

Elsevier BV

Subject

Cancer Research,Radiology, Nuclear Medicine and imaging,Oncology,Radiation

Reference37 articles.

1. Autologous haematopoietic stem-cell transplantation versus bortezomib–melphalan–prednisone, with or without bortezomib–lenalidomide–dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study

2. Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up;Dimopoulos;Ann Oncol,2021

3. Intravenous busulfan plus melphalan versus melphalan alone as conditioning regimen for patients with multiple myeloma;Blanes;Ann Hematol,2019

4. Bortezomib and high-dose melphalan as conditioning regimen before autologous stem cell transplantation in patients with de novo multiple myeloma: A phase 2 study of the Intergroupe Francophone du Myélome (IFM);Roussel;Blood,2010

5. Comparison of 200 mg/m2 melphalan and 8 Gy total body irradiation plus 140 mg/m2 melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myelome 9502 randomized trial

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Is There Still a Role for Stem Cell Transplantation in Multiple Myeloma?;Hematology/Oncology Clinics of North America;2023-12

2. In Regard to Cailleteau et al.;International Journal of Radiation Oncology*Biology*Physics;2023-07

3. In Reply to Tsai et al.;International Journal of Radiation Oncology*Biology*Physics;2023-07

4. Radiotherapy in Combination with Systemic Therapy for Multiple Myeloma—A Critical Toxicity Evaluation in the Modern Treatment Era;Cancers;2023-05-25

5. Total marrow irradiation in hematopoietic stem cell transplantation for hematologic malignancies;Frontiers in Medicine;2023-04-20